Press Releases

Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer

Posted on October 1, 2015

KENILWORTH, N.J. & HOUSTON, Oct.1, 2015 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and DNAtrix today announced they have entered into an oncology clinical.. read more

DNAtrix Collaborators Present Data on a Novel Oncolytic Adenovirus Expressing OX40 Ligand that Promotes Antitumor Immunity

Posted on June 16, 2015

Houston, TX – June 16, 2015. DNAtrix, Inc., a leader in oncolytic virus therapy, has announced that Juan Fueyo, M.D., professor in the Department of Neuro-Oncology and Director of the.. read more

DNAtrix Awarded Most Promising Life Science Company at 2015 Texas Life Science Forum

Posted on June 8, 2015

Houston, TX – DNAtrix was named one of the Most Promising Life Science Companies at the 2015 Texas Life Science Forum held in Houston, Texas on May 20, 2015. The.. read more

Alcyone Lifesciences and DNAtrix Enter Clinical Collaboration for Brain Cancer

Posted on May 20, 2015

Collaboration Combines Companies’ Expertise in Oncolytic Virus Therapy and Targeted Drug Delivery Lowell, MA and Houston, TX – May 19, 2015. Alcyone Lifesciences, Inc., a leader in neural intervention systems.. read more


Posted on October 14, 2014

San Diego, Calif.  –October 14, 2014 - DNAtrix, a clinical-stage oncolytic immunotherapy company, announced that it has completed a $20M Series B equity financing.  New investor Morningside Ventures led the.. read more